Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma
- 15 November 2004
- journal article
- Published by American Society of Hematology in Blood
- Vol. 104 (10) , 3361-3363
- https://doi.org/10.1182/blood-2004-05-2031
Abstract
To improve the antimyeloma effect of donor lymphocyte infusion (DLI) after allogeneic stem cell transplantation in multiple myeloma, we investigated in a phase 1/2 study the effect of low-dose thalidomide (100 mg) followed by DLI in 18 patients with progressive disease or residual disease and prior ineffective DLI after allografting. The overall response rate was 67%, including 22% complete remission. Major toxicity of thalidomide was weakness grade I/II (68%) and peripheral neuropathy grade I/II (28%). Only 2 patients experienced mild grade I acute graft versus host disease (aGvHD) of the skin, while no grades II to IV aGvHD was seen. De novo limited chronic GvHD (cGvHD) was seen in 2 patients (11%). The 2-year estimated overall and progression-free survival were 100% and 84%, respectively. Adoptive immunotherapy with low-dose thalidomide and DLI induces a strong antimyeloma effect with low incidence of graft versus host disease.Keywords
This publication has 21 references indexed in Scilit:
- The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myelomaBlood, 2004
- Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responsesBlood, 2004
- Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myelomaLeukemia, 2003
- Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myelomaBlood, 2003
- Thalidomide as initial therapy for early-stage myelomaLeukemia, 2003
- Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortalityBlood, 2002
- Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myelomaBlood, 2002
- Donor leukocyte infusions for multiple myelomaBone Marrow Transplantation, 2000
- Therapy with thalidomide in refractory multiple myeloma patients — the revival of an old drugBritish Journal of Haematology, 2000
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999